Stakeholders decry EU pediatric plan timing & class waiver system
This article was originally published in Scrip
The EU's call for ways of improving the paediatric investigation plan (PIP) system has drawn some interesting criticisms and recommendations on a range of issues such as the timing of PIP submissions, the extent of the information that should be included in a PIP, and problems with the class waiver system.
You may also be interested in...
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.